Discovery and characterization of a functional scFv for CCR2 inhibition via an extracellular loop

被引:2
|
作者
Jasiewicz, Natalie E. [1 ]
Brown, Adam D. [1 ]
Deci, Michael [2 ]
Matysiak, Silvina [3 ]
Earp, H. Shelton [4 ]
Nguyen, Juliane [1 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengineering & Mol Pharmaceut, Chapel Hill, NC 27599 USA
[2] Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY USA
[3] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
Chemokine receptors; scFv; Cellular migration; Phenotype switching; In silico; Molecular docking; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SINGLE-CHAIN FV; WEB SERVER; RECEPTOR; BINDING; PF-04634817; MACROPHAGES; ANTAGONIST; EXPRESSION; AFFINITY;
D O I
10.1016/j.ijpharm.2022.122547
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chemokine receptor CCR2 plays a key role in cellular migration and inflammatory processes. While tremendous progress has been made in elucidating CCR2 function and inhibition, the majority of approaches target its N-terminal domain and less is known about the function of the remaining extracellular loops and their potential as targets. Here, we used phage display to identify an antibody-derived scFv (single chain variable fragment) clone that specifically targets the second extracellular epitope of CCR2 (ECL2) for inhibition. Using in silico molecular docking, we identified six potential primary binding conformations of the novel scFv to the specified CCR2 epitope. In silico molecular dynamic analysis was used to determine conformational stability and identify protein-protein interactions. Umbrella sampling of a range of configurations with incrementally increasing separation of scFv and target generated by force pulling simulations was used to calculate binding energies. Downstream characterization by ELISA showed high binding affinity of the ECL2-scFv to CCR2. Furthermore, we showed that blocking the second extracellular loop inhibits macrophage migration and polarized macrophages towards M1 inflammatory cytokine production as potently as lipopolysaccharide (LPS). These studies highlight the applicability of epitope-specific targeting, emphasize the importance of in silico predictive modeling, and warrant further investigation into the role of the remaining epitopes of CCR2.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development
    Begin-Lavallee, Valerie
    Midavaine, Elora
    Dansereau, Marc-Andre
    Tetreault, Pascal
    Longpre, Jean-Michel
    Jacobi, Ashley M.
    Rose, Scott D.
    Behlke, Mark A.
    Beaudet, Nicolas
    Sarret, Philippe
    MOLECULAR PAIN, 2016, 12
  • [22] Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer
    Jung, Heiyoun
    Ertl, Linda
    Janson, Christine
    Schall, Thomas
    Charo, Israel
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [23] Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement
    Deci, Michael B.
    Ferguson, Scott W.
    Scatigno, Sydney L.
    Nguyen, Juliane
    MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2721 - 2731
  • [24] CCR2 inhibition sequesters multiple subsets of leukocytes in the bone marrow
    Naoki Fujimura
    Baohui Xu
    Jackson Dalman
    Hongping Deng
    Kohji Aoyama
    Ronald L Dalman
    Scientific Reports, 5
  • [25] Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists
    Cherney, Robert J.
    Brogan, John B.
    Mo, Ruowei
    Lo, Yvonne C.
    Yang, Gengjie
    Miller, Persymphonie B.
    Scherle, Peggy A.
    Molino, Bruce F.
    Carter, Percy H.
    Decicco, Carl P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 597 - 601
  • [26] Ccr2 Inhibition Impacts Abdominal Aortic Aneurysm Rupture In Rodents
    Zaghloul, Mohamed S.
    Elizondo-Benedetto, Santiago
    Arif, Batool
    Detering, Lisa
    Luehmann, Hannah
    Sultan, Debbie
    Heo, Gyu Seong
    Gropler, Robert J.
    Liu, Yongjian
    Zayed, Mohamed A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [27] CCR2 inhibition sequesters multiple subsets of leukocytes in the bone marrow
    Fujimura, Naoki
    Xu, Baohui
    Dalman, Jackson
    Deng, Hongping
    Aoyama, Kohji
    Dalman, Ronald L.
    SCIENTIFIC REPORTS, 2015, 5
  • [28] CCR2 Signaling Inhibition Improves Tumor Control in Pancreatic Cancer
    Mitchem, J.
    Sanford, D.
    Porembka, M.
    Lin, G.
    Goedegebuure, S. P.
    Linehan, D. C.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S44 - S44
  • [29] Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2
    Zweemer, Annelien J. M.
    Bunnik, Julia
    Veenhuizen, Margo
    Miraglia, Fabiana
    Lenselink, Eelke B.
    Vilums, Maris
    de Vries, Henk
    Gibert, Arthur
    Thiele, Stefanie
    Rosenkilde, Mette M.
    IJzerman, Adriaan P.
    Heitman, Laura H.
    MOLECULAR PHARMACOLOGY, 2014, 86 (04) : 358 - 368
  • [30] Discovery of novel trisubstituted cyclohexane derivatives as potent and bioavailable CCR2 antagonists
    Cherney, Robert J.
    Mo, Ruowei
    Yang, Michael G.
    Xiao, Zili
    Meyer, Dayton T.
    Zhao, Qihong
    Mandlekar, Sandhya
    Lo, Yvonne C.
    Yang, Gengjie
    Miller, Persymphonie B.
    Scherle, Peggy A.
    Wasserman, Zelda R.
    Jezak, Heather
    Solomon, Kimberly A.
    Tebben, Andrew J.
    Cvijic, Mary Ellen
    Barrish, Joel C.
    Decicco, Carl P.
    Carter, Percy H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245